Ken Griffin Schrodinger, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$18.05 - $24.02 $274,360 - $365,104	15,200 Added 21.08%	87,300 $1.62 Million
Q2 2024 Aug 14, 2024	SELL	$18.65 - $28.5 $430,814 - $658,350	-23,100 Reduced 24.26%	72,100 $1.39 Million
Q1 2024 May 15, 2024	SELL	$24.74 - $35.13 $1.95 Million - $2.76 Million	-78,700 Reduced 45.26%	95,200 $2.57 Million
Q4 2023 Feb 14, 2024	BUY	$21.62 - $37.21 $2.17 Million - $3.74 Million	100,600 Added 137.24%	173,900 $6.23 Million
Q3 2023 Nov 14, 2023	SELL	$27.34 - $55.37 $8.9 Million - $18 Million	-325,600 Reduced 81.62%	73,300 $2.07 Million
Q2 2023 Aug 14, 2023	BUY	$26.1 - $49.92 $9.35 Million - $17.9 Million	358,300 Added 882.51%	398,900 $19.9 Million
Q1 2023 May 15, 2023	SELL	$18.09 - $27.61 $1.46 Million - $2.23 Million	-80,900 Reduced 66.58%	40,600 $1.07 Million
Q4 2022 Feb 14, 2023	SELL	$16.24 - $26.38 $591,136 - $960,232	-36,400 Reduced 23.05%	121,500 $2.27 Million
Q3 2022 Nov 14, 2022	BUY	$23.95 - $34.71 $270,635 - $392,223	11,300 Added 7.71%	157,900 $3.94 Million

236

61M

726K

329K

Ticker SDGR
Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Shares Outstandng 62,028,400
Market Cap $1.33B
Description
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.